172 CHAPTER 6 29. Meijer TG, Nguyen L, Van Hoeck A, et al. Functional RECAP (REpair CAPacity) assay identifies homologous recombination deficiency undetected by DNA-based BRCAness tests. Oncogene 2022;41(26):3498-3506. (In English). DOI: 10.1038/s41388-022-02363-1. 30. Davies H, Glodzik D, Morganella S, et al. HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. Nature Medicine 2017;23(4):517-+. (In English). DOI: 10.1038/ nm.4292. 31. Nguyen L, Martens JWM, Van Hoeck A, Cuppen E. Pan-cancer landscape of homologous recombination deficiency. Nature Communications 2020;11(1) (In English). DOI: ARTN 5584 10.1038/s41467020-19406-4. 32. Wen PY, Stein A, van den Bent M, et al. Dabrafenib plus trametinib in patients with BRAF(V600E)-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial. Lancet Oncol 2022;23(1):53-64. (In English). DOI: 10.1016/S1470-2045(21)00578-7. 33. Subbiah V, Kreitman RJ, Wainberg ZA, et al. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study. Ann Oncol 2022;33(4):406-415. (In English). DOI: 10.1016/j.annonc.2021.12.014. 34. Motzer RJ, Hutson TE, Tomczak P, et al. Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology 2009;27(22):3584-3590. (In English). DOI: 10.1200/Jco.2008.20.1293. 35. Stommel JM, Kimmelman AC, Ying H, et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 2007;318(5848):287-90. DOI: 10.1126/science.1142946. 36. Klaeger S, Heinzlmeir S, Wilhelm M, et al. The target landscape of clinical kinase drugs. Science 2017;358(6367) (In English). DOI: ARTN eaan4368 10.1126/science.aan4368. 37. Motzer R, Rini BI, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol 2019;20(10):1370-1385. (In English). DOI: 10.1016/S1470-2045(19)30413-9. 38. Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma. New Engl J Med 2013;369(8):722-731. (In English). DOI: 10.1056/NEJMoa1303989. 39. Beuselinck B, Job S, Becht E, et al. Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated with Sunitinib Response in the Metastatic Setting. Clinical Cancer Research 2015;21(6):13291339. (In English). DOI: 10.1158/1078-0432.Ccr-14-1128. 40. Feng CC, Li YQ, Li KP, et al. PFKFB4 is overexpressed in clear-cell renal cell carcinoma promoting pentose phosphate pathway that mediates Sunitinib resistance (vol 40, 308, 2021). J Exp Clin Canc Res 2021;40(1) (In English). DOI: ARTN 379 10.1186/s13046-021-02165-5. 41. van der Mijn JC, Broxterman HJ, Knol JC, et al. Sunitinib activates Axl signaling in renal cell cancer. Int J Cancer 2016;138(12):3002-10. DOI: 10.1002/ijc.30022. 42. Clark DJ, Dhanasekaran SM, Petralia F, et al. Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma. Cell 2019;179(4):964-983 e31. DOI: 10.1016/j.cell.2019.10.007.
RkJQdWJsaXNoZXIy MTk4NDMw